Japanese drugmaker Ono Pharmaceuticals (TYO: 4528) has been granted approval from the Taiwan Food and Drug Administration to market Opdivo (Nivolumab) in a fourth indication, head and neck cancer.
The immuno-oncology drug is already approved in Taiwan for certain patient types within melanoma, non-small cell lung cancer and renal cell carcinoma.
The drug’s discoverer signed a licensing agreement with Bristol-Myers Squibb (NYSE: BMY) in 2011, allowing the American firm to commercialize Opdivo outside of Japan, South Korea and Taiwan.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze